Hofseth Biocare ASA
Hofseth Biocare ASA is a food processing company that develops and commercializes functional food and beverage products, primarily targeting health-conscious consumers.
Business. Hofseth Biocare ASA (HBC.OL) is a food processing company operating within the Consumer Non-Cyclicals sector. The firm is headquartered in Norway and is primarily listed on the Oslo Børs. Specific details regarding its operating segments and geographic revenue mix are not available.
- EarningsH1 2026 earnings (expected)2026-08-21 · estimated
- EarningsQ3 2026 earnings (expected)2026-11-06 · estimated
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsH1 2026 earnings (expected)2026-08-21 · estimated
- EarningsQ3 2026 earnings (expected)2026-11-06 · estimated
- EarningsQ4 2026 earnings (expected)2027-02-12 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Hofseth Biocare ASA (HBC.OL) is a food processing company operating within the Consumer Non-Cyclicals sector. The firm is headquartered in Norway and is primarily listed on the Oslo Børs. Specific details regarding its operating segments and geographic revenue mix are not available.
Hofseth Biocare operates with a negative equity position of NOK -74.84 million and a total liabilities-to-equity ratio of -4.02, indicating a highly leveraged capital structure. The company's liquidity position is rated as medium, with a current ratio of 0.67, suggesting limited short-term liquidity to cover immediate obligations. The enterprise value to revenue ratio of 3.17 is below the typical range for early-stage food processing firms, reflecting the company's current financial challenges.
Profitability metrics show a return on equity of 1.80%, which is modest and below the industry median for food processing firms, while the return on assets is negative at -0.34%, indicating asset underperformance. The company reported a net loss of NOK -134.88 million for the period, with an operating loss of NOK -112.35 million, highlighting significant operational inefficiencies.
The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification, which increases exposure to regional market risks. Hofseth Biocare's revenue for the period was NOK 256.34 million, but the company has not provided segment-specific revenue breakdowns, limiting visibility into growth drivers.
Looking ahead, Hofseth Biocare is expected to face continued financial pressure, with no clear path to profitability in the near term. The company's operating cash flow was negative at NOK -27.81 million, and free cash flow was NOK -116.03 million, indicating a reliance on external financing to fund operations. The capital expenditure of NOK -20.47 million suggests ongoing investment in infrastructure, but without a corresponding increase in revenue, this may not be sustainable.
The company's risk profile is elevated due to its negative net cash position and high debt load. The risk assessment indicates a low probability of dilution in the near term, but the company's equity position is highly vulnerable to further declines in asset value or increases in liabilities. No recent filings or transcripts have been disclosed that provide insight into strategic changes or operational improvements.
Recent financial disclosures show no material changes in the company's risk profile or capital structure. The company's debt-to-equity ratio of -4.02 is among the highest in the industry, and its liquidity risk remains a concern. No new product launches or market expansions have been reported that would significantly alter the company's trajectory.
- Hofseth Biocare is operating with a negative equity position and high leverage, indicating significant financial risk.
- The company's profitability metrics are weak, with a negative return on assets and low return on equity.
- Revenue is concentrated in a single business segment, increasing exposure to market-specific risks.
- The company's liquidity position is weak, with a current ratio below 1 and negative operating cash flow.
- No recent strategic or operational changes have been disclosed that would improve the company's financial outlook.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Ev To Revenueenterprise_value / revenue
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Hofseth Biocare ASA Market data — financials · 2026-05-28
Ownership & reference
Leadership
- Jon Olav ØdegårdCEO
Insider activity
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- Current ratio (FY 2024-12-31): 0.98xDerived (calculated)
- Net margin (FY 2024-12-31): -36.7%Derived (calculated)
- Return on assets (FY 2024-12-31): -26.0%Derived (calculated)
- Debt-to-equity (FY 2024-12-31): 2.13xDerived (calculated)
- Return on equity (FY 2024-12-31): -81.3%Derived (calculated)
- Total equity & liabilities (annual): NOK 377.25MBRREG filing
- Current liabilities (annual): NOK 159.91MBRREG filing
- Total assets (annual): NOK 377.25MBRREG filing
- Revenue (annual): NOK 267.03MBRREG filing
- Total operating expenses (annual): NOK 355.45MBRREG filing
- Current assets (annual): NOK 157.03MBRREG filing
- Finance expense (annual): NOK 21.31MBRREG filing
- Total liabilities (annual): NOK 256.83MBRREG filing
- Shareholders' equity (annual): NOK 120.42MBRREG filing
- Net income (annual): NOK -97.9MBRREG filing
- Pre-tax income (annual): NOK -97.9MBRREG filing
- Operating income (annual): NOK -88.43MBRREG filing
- Non current assets (annual): NOK 220.22MBRREG filing
- Non current liabilities (annual): NOK 96.92MBRREG filing